RESEARCH ARTICLE

Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8

Katy Billot,1 Charline Coquil,1 Benoit Villiers,1 Beatrice Josselin-Foll,2 Nathalie Desban,2 Claire Delehouze,2 Nassima Oumata,1 Yannick Le Meur,3 Alessandra Boletta,4 Thomas Weimbs,5 Melanie Grosch,6 Ralph Witzgall,6 Sophie Saunier,7 Evelyne Fischer,8 Marco Pontoglio,9 Alain Fautrel,9 Michal Mrug,10,11 Darren Wallace,12 Pamela V. Tran,12,13 Marie Trudel,14 Nikolay Bukanov,15 Oxana Ibraghimov-Beskrovnaya,15 and Laurent Meijer1

1ManRos Therapeutics, Centre de Perharidy, Roscoff, France; 2CNRS “Protein Phosphorylation and Human Disease Group, Station Biologique, Roscoff Cedex, Bretagne, France; 3Service de Nephrologie, Centre Hospitalier Universitaire La Cavale Blanche, Rue Tanguy Prigent, Brest Cedex, France; 4Division of Genetics and Cell Biology, DIBIT San Raffaele Scientific Institute, Milan, Italy; 5Department of Molecular, Cellular, and Developmental Biology, Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, California; 6University of Regensburg, Institute for Molecular and Cellular Anatomy, Universitätsstrasse 31, Regensburg, Germany; 7INSERM U1163, Institut Imagine, Paris, France; 8“Expression Génique, Développement et Maladies”, Equipe 26/INSERM U1016/CNRS UMR 8104/Université Paris-Descartes, Institut Cochin, Département Génétique & Développement, Paris, France; 9Université de Rennes 1, H2P2 Histopathology Core Facility, Rennes Cedex, France; 10Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama; 11Department of Veterans Affairs Medical Center, Birmingham, Alabama; 12University of Kansas Medical Center, The Jared Grantham Kidney Institute, Kansas City, Kansas; 13University of Kansas Medical Center, Department of Anatomy and Cell Biology, Kansas City, Kansas; 14Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Montreal, Quebec, Canada; and 15Sanofi Genzyme, Rare Renal and Bone Diseases, Framingham, Massachusetts

Submitted 3 October 2017; accepted in final form 5 March 2018

INTRODUCTION

Polycystic kidney disease (PKD) is characterized by the progressive growth of fluid-filled cysts originating in renal tubules and can lead to end-stage renal disease (ESRD) (reviewed in Refs. 1, 4, 52, 76, and 78). PKD is considered a ciliopathy, i.e. a disease linked to abnormalities in the structure/functions of primary cilia (2, 36, 39, 54). Autosomal Dominant PKD (ADPKD) is among the most common life-threatening genetic disorders (occurring in 1/200–1,000 individuals worldwide). ADPKD is caused by >1,800 pathogenic mutations in the Polycystic Kidney Disease 1 (PKD1) gene (78%), PKD2 gene (15%) or other genes (7%). PKD1 and PKD2 encode polycystin-1 and polycystin-2, respectively. Autosomal Recessive PKD (AR-PKD) (1/20,000 individuals) results from mutations in the PKHD1 gene, encoding fibrocystin. Besides the modestly active Tolvaptan (9) recently approved for the treatment of ADPKD, there is no effective therapy for PKD, leaving transplantation or dialysis as the only treatment once ESRD has been reached. Yet numerous novel therapies are currently under evaluation (reviewed in Refs. 49, 57, 64, and 79).

Abnormalities in protein kinase regulation and phosphorylation are associated with numerous diseases. Targeting specific kinases constitutes a major approach for the pharmaceutical industry in its search for new therapeutics. More than 250 kinase inhibitors have undergone clinical trials, and approxi-
mately 37 products have reached the market (reviewed in Refs. 63 and 93–95). The discovery of the beneficial effects of the purine (R)-roscovitine (hereafter referred to as roscovitine) in three PKD mouse models ignited interest in pharmacological inhibitors of CDKs as potential anti-PKD drugs (13, 14, 39, 48, 66, 67, 85). Indeed, roscovitine induced cell cycle arrest, decreased apoptotic cell death of cystic-lining epithelial cells, and markedly reduced cystic volume and improved renal function. CDKs have been a major target in the search for specific pharmacological inhibitors because of their implication in numerous diseases, including cancers, neurodegenerative disorders, inflammation, renal diseases, and viral infections, etc. Pharmacological inhibitors of CDKs have also been evaluated in various kidney diseases such as glomerulonephritis (35, 62, 70, 80), lupus nephritis (100), collapsing glomerulopathy (32), cisplatin-induced nephrotoxicity (37, 38, 72, 73), kidney transplantation (69), and PKD (13, 14, 48, 66, 67, 85). Among the inhibitors initially developed as potential anticancer drug candidates, roscovitine is currently in phase 2 clinical evaluation against non-small cell lung, nasopharyngeal, and breast cancers. Cushing syndrome and cystic fibrosis are reviewed in Refs. 19 and 58–60. More recently a roscovitine derivative, (S)-CR8 (hereafter referred to as CR8), was found to be ~100-fold more potent at inducing tumor cell apoptosis (5, 6) and was also more potent at reducing cystogenesis in an ADPKD mouse model (13). An extensive study of the selectivity of roscovitine and CR8 showed that casein kinases 1 (CK1ε), CK1ε in particular, are also main targets of roscovitine and CR8 (23). Because all effects of roscovitine/CR8 in PKD have been attributed so far to an inhibition of CDKs, we were interested to find out whether polycystic kidney CK1 could be involved as targets of roscovitine/CR8 and whether CK1 de-regulation could be observed in PKD.

Here, we show that CK1ε indeed represent targets of roscovitine and CR8 in human and mouse polycystic kidneys. CK1ε is systematically overexpressed (at mRNA and protein levels) in polycystic human and murine kidneys compared with healthy kidneys, regardless of the underlying genetic mutation. Additionally, the CK1ε isoform pattern is shifted, and the catalytic activities of both CK1ε and CK1α are increased in polycystic kidneys. Thus, inhibition of CK1ε and CK1α could contribute to the long-lasting attenuating effects of roscovitine and CR8 on cystogenesis. CDKs and CK1s thus might constitute a dual therapeutic target to develop kinase inhibitory PKD drug candidates.

**MATERIALS AND METHODS**

All animal handling and experiments were carried out following protocols approved by all Institutional Animal Care and Use Committees at the San Raffaele Scientific Institute (IACUC-736; ultimately approved by the Italian Ministry of Health), the University of California Santa Barbara, the local government in Regensburg, Germany, in accordance with German Animal Protection law, INSERM (B 75-14-02), the University of Alabama at Birmingham, the Institut de Recherches Cliniques de Montréal, the Canadian Council on Animal Care, and Sanofi-Genzyme (Framingham, MA).

**Buffers**

**Bead buffer.** Bead Buffer (BB) consisted of 50 mM Tris, pH 7.4, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, 5 mM NaF, 0.1% Nonidet P-40, and 1× Roche complete protease inhibitors was used.

**Blocking buffer.** Blocking buffer consisted of 1 M ethanolamine, pH 8.0.

**Coupling buffer.** Coupling buffer consisted of 0.1 M NaHCO3 and 0.2 M NaCl, pH 8.3.

**Homogenization buffer.** Homogenization buffer consisted of 25 mM MOPS, pH 7.2, 15 mM EGTA, 15 mM MgCl2, 60 mM β-glycerophosphate, 15 mM p-nitrophenylphosphate, 2 mM dithiothreitol (DTT), 1 mM sodium orthovanadate, 1 mM NaF, 1 mM phenylphosphate disodium, and 1× Roche complete protease inhibitors was used.

**Washing buffer.** Washing buffer consisted of 0.1 M CH3COONa, pH 4.0.

**Assay buffer C.** Assay buffer C consisted of 25 mM MOPS, pH 7.2, 5 mM EGTA, 15 mM MgCl2, 60 mM β-glycerophosphate, 30 mM p-nitrophenylphosphate, 2 mM dithiothreitol, 0.1 mM sodium orthovanadate, and 1 mM phenylphosphate disodium.

All chemicals were from Sigma-Aldrich (St. Quentin Fallavier, France), except for the protease inhibitor cocktail (Roche, Mannheim, Germany).

**Antibodies and Reagents**

Antibodies against the following proteins were obtained commercially: CDK2 (sc-163, polyclonal, 1:500; Santa Cruz Biotechnology, Dallas, TX), CDK5 J-3 (sc-6247, monoclonal, 1:500; Santa Cruz Biotechnology), CDK9 (C12F7, monoclonal, 1:1,000; Cell Signaling Technology, Danvers, MA), CK1ε (2655, polyclonal, 1:1,000 (Cell Signaling Technology) and polyclonal, sc-6477, 2 μg/IP (Santa Cruz Biotechnology), CK1ε (610445, monoclonal, 1:500 or 2 μg/IP; BD Transduction Laboratories, Pont de Claix, France), p21cip1 (sc-97, monoclonal, 1:500; Santa Cruz Biotechnology), and ERK1/2 (polyclonal, 1:4,000; Sigma-Aldrich, M7927). Polyclonal anti-PDXK antibodies were generated as previously reported (3) and used at a 1:500 dilution. Polyclonal anti-GDE antibodies were generously provided by Dr. Tomoichiro Asano (Department of Internal Medicine, University of Tokyo). These antibodies were validated by various ways; cell treatment with siRNA or shRNA of corresponding protein (CDK2, CDK5, CK1α, CK1ε, and p21cip1) results in lower Western blot (WB) signal by antibody, positive WB signal after affinity purification on azin-2 (CK1s), a fragment of azin, a scaffolding protein known to bind CK1 (77), positive WB signal after affinity purification of extracts on roscovitine/CR8 ligand (CDKs, CK1s, PDXXK, ERKs, and GDE), which was confirmed by mass spectrometry, WB signal competed out for binding of CK1s and CDKs on CR8 beads by CK1 inhibitors and CDK inhibitors, respectively, antibodies immunoprecipitated kinases catalytically active toward CK1 substrates (CK1α, CK1ε), and increased WB signal when protein is overexpressed (p21cip1, ERK1/2, PDXXK).

(R)-roscovitine and (S)-CR8 were synthesized by ManRos Therapeutics, as previously described (65). CK1 pan-inhibitors (IC261 and D4476) and a CK1ε-specific inhibitor (PF4800567) were provided by Sigma-Aldrich and Tocris (Bristol, UK), respectively. Reagents were solubilized at 10 mM in 100% dimethylsulfoxide (DMSO).

**Tissues from Animal Models and Human Kidneys**

Animal tissues were provided by different contributors (Table 1). They were snap-frozen and stored at −80°C until further use. Normal human kidney (NHK) and ADPKD renal tissues were obtained from the Kidney Institute, University of Kansas Medical Center (D. Wallace).

**Kinase Interaction Panel (DiscovRx KinomeScan)**

Assays were performed essentially as described previously (17, 23). For most assays, kinase-tagged T7 phage stages were grown in parallel in 24-well blocks in an E. coli host derived from the BL21...
Table 1. *Murine models used in this study*

<table>
<thead>
<tr>
<th>Model</th>
<th>Name</th>
<th>Mutation/Deletion</th>
<th>Age/Disease Stage</th>
<th>Provider</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Jck</em></td>
<td>juvenile cystic kidney</td>
<td>Missense mutation on Nek8 gene, G448V, in the highly conserved RCC1 domain of Nek8.</td>
<td>26–64 days (Fig. 7); 64 days in all other experiments/high level of cystogenesis</td>
<td>N. Bukanov and O. Ibraghimov-Beskrovnaya.</td>
</tr>
<tr>
<td><em>Bpk</em></td>
<td>BALB/c polycystic kidney</td>
<td>Abnormal 3' coding region of the <em>biccaul C homolog 1</em> gene, <em>Bicc1</em></td>
<td>Postnatal day 21/very advanced disease</td>
<td>T. Weimbs</td>
</tr>
<tr>
<td><em>Pkd1flox/−:Ksp-Cre</em></td>
<td>Polycystic kidney disease 1 (polycystin 1)</td>
<td><em>Pkd1</em> gene inactivated in kidneys</td>
<td>P7/severe development of cystogenesis (mice die at P13)</td>
<td>A. Boletta</td>
</tr>
<tr>
<td><em>Pkd1 extra 11</em></td>
<td>Polycystic kidney disease (polycystin 1)</td>
<td>Deletion of a fragment of the <em>Pkd1</em> gene. Expresses only extracellular domain of Pkd1</td>
<td>15–24 mo</td>
<td>M. Trudel</td>
</tr>
<tr>
<td><em>Pkd1flox/−:Cyp</em></td>
<td>Polycystic kidney disease 1 (polycystin 1)</td>
<td>Mutation on <em>Pkd1</em> gene in renal and extra renal tissues</td>
<td>5–7 mo</td>
<td>M. Trudel</td>
</tr>
<tr>
<td><em>Pkd1-cKO</em></td>
<td>Polycystic kidney disease 1 (polycystin 1)</td>
<td>Conditional knockout of <em>Pkd1</em> gene</td>
<td>52–54 days/moderate level of cystogenesis</td>
<td>N. Bukanov and O. Ibraghimov-Beskrovnaya</td>
</tr>
<tr>
<td><em>Pcy</em></td>
<td>Polycystic</td>
<td>Missense mutation (T1841G) in the mouse ortholog of the human <em>Nphp3</em> gene (encoding Nephrocystin-3)</td>
<td>30 wk/mild level of cystogenesis</td>
<td>N. Bukanov and O. Ibraghimov-Beskrovnaya</td>
</tr>
<tr>
<td><em>Pkd2-cKO</em></td>
<td>Polycystic kidney disease 2 (polycystin 2)</td>
<td><em>Pkd2</em> gene inactivation in renal collecting ducts</td>
<td>4 wk/severe cystogenesis</td>
<td>M. Grosh and R. Witzgall</td>
</tr>
<tr>
<td><em>Cpk</em></td>
<td>Congenital polycystic kidney</td>
<td>Mutation in the <em>Cysl</em> gene</td>
<td>10 or 21 days</td>
<td>M. Mrug</td>
</tr>
<tr>
<td><em>HNF1β</em></td>
<td>Hepatocyte nuclear factor β</td>
<td>Knockout of <em>Hnf1β</em> gene in kidneys</td>
<td>21–28 days/mild to severe cystogenesis</td>
<td>E. Fischer and M. Pontoglio</td>
</tr>
<tr>
<td><em>Thm1-cKO</em></td>
<td>Tetraicopeptide repeat-containing hedgehog modulator-1</td>
<td>Conditional knockout of <em>Thm1</em> gene (ROSA26-Cre&lt;sup&gt;ERT&lt;/sup&gt;)</td>
<td>Gene deletion at P0/analysis at P42</td>
<td>P. V. Tran</td>
</tr>
<tr>
<td><em>Nphp4</em></td>
<td>Nephronophthisis 4</td>
<td>Knockout of <em>Nphp4</em> gene</td>
<td>4 or 8 mo/no cysts</td>
<td>S. Saunier</td>
</tr>
</tbody>
</table>

Strain.* E. coli* were grown to log phase and infected with T7 phage from a frozen stock (multiplicity of infection ~0.1) and incubated with shaking at 32°C until they were lysed (~90 min). The lysates were centrifuged (6,000 g) and filtered (0.2 μm) to remove cell debris. The remaining kinases were produced in human embryonic kidney-293 cells and subsequently tagged with DNA for quantitative PCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 min at room temperature (RT) to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock, 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce nonspecific phase binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, 6 mM DTT). An 11-point threefold serial dilution of each test compound was prepared in 100% DMSO at a 1× binding concentration that was subsequently diluted to 1× in the assay. All reactions were performed in polystyrene 96-well plates in a final volume of 0.135 ml. The assay plates were incubated at RT with shaking for 1 h, and the affinity beads were washed four times with wash buffer (1× PBS, 0.05% Tween 20). The beads were then resuspended in elution buffer (1× PBS, 0.05% Tween 20, 0.5 μM nonbiotinylated affinity ligand) and incubated at RT with shaking for 30 min. The kinase concentration in eluates was measured by quantitative PCR. *Kd* was determined using 11 dose-response curves (top concentration 30 μM, 3-fold dilutions down) that were performed in duplicate. The *Kd* reported represents the average of the duplicates, and a value of 40,000 nM indicates that no binding was seen at the highest concentration tested (>30 μM).

**Affinity Chromatography Purification on Immobilized Roscovitine and CR8**

Preparation of roscovitine and CR8-agarose beads. CNBr-activated sepharose 4B (Sigma-Aldrich) was swollen in cold 1 mM HCl for 30 min. Beads were then activated with coupling buffer containing roscovitine plus linker solution or CR8 plus linker solution at 20 mM. Roscovitine or CR8 with a linker were synthesized as described (3, 23) and coupled overnight, protected from light, under constant rotation at room temperature (RT). After removal of the supernatant, the beads were washed with coupling buffer and residual active sites quenched using blocking buffer for 2 h under constant rotation at RT. Beads were washed with washing buffer and BB and brought to 20% suspension in BB. They were stored at 4°C until further use.

**Affinity chromatography of roscovitine and CR8-interacting proteins.** Just before use, 100 μl of packed beads was washed with 1 ml of BB and resuspended to a 20% suspension in this buffer. The tissue extract supernatant (700 μg of total protein) was then added, and the volume was adjusted to 1 ml with BB. The tubes were rotated at 4°C for 30 min. After a brief spin at 100 g and removal of the supernatant, the beads were washed four times with BB before addition of 45 μl of 1× sample loading buffer (Invitrogen) with 200 mM DTT. Following heat denaturation for 3 min and a 1-min spin at 10,000 g, the bound proteins were analyzed by SDS-PAGE and Western blotting (WB).

**Competition experiments.** Protein extracts were incubated with unattached (free) molecules (CK1 inhibitors) for 10 min at 4°C under constant rotation before the affinity chromatography step.
Expression of GST-axin 2 fusion protein. The GST-axin 2 fusion protein (77) was expressed in *E. coli* KRX (Stratagene; Agilent Technologies, Les Ulis, France) after induction with 0.5 mM isopropryl β-D-1-thiogalactopyranoside (IPTG) at 37°C for 3 h. Bacteria were resuspended in 20–30 ml of lysis buffer, 1 mg/ml lysozyme was added, and the mix was rotated for 10 min at RT. Lysis extracts were sonicated for 2 min. Six mM MgCl2 and 25 U/ml benzonase were added and incubation ensued for 15 min at 4°C, followed by a spin at 12,000 g for 30 min at 4°C. Soluble fractions were transferred to glutathione beads, followed by a 1-h incubation at 4°C. The beads were washed with lysis buffer three times and once with BB and brought to a 20% suspension in BB. They were stored until further use at 4°C.

Affinity Chromatography Purification of CK1 on Axin Beads

Purification of CK1 from kidney lysates. Kidney lysate (600 μg), prepared as described below, was incubated with 100 μl of GST-axin 2-coupled glutathione beads for 30 min at 4°C under constant rotation. The beads were washed four times with BB before the addition of 90 μl of protein G sepharose beads (40% slurry in BB; Sigma-Aldrich) at 4°C for 1 h. CK1ε or CK1α were immunoprecipitated with 2 μg of CK1ε or CK1α antibodies, respectively, from precleared lysates by 1 h of incubation at 4°C, followed by 1 h of incubation at 4°C with 25 μl of protein G sepharose beads. Immunoprecipitates were washed four times with BB before the addition of 45 μl 1× sample loaded buffer with 200 mM DTT. Beads were then denatured for 3 min at 99°C. The supernatant was recovered after a 1-min centrifugation at 10,000 g. Diluted and precleared extracts were diluted to one-half in 2× sample loaded buffer containing 400 mM DTT. Immunoprecipitated proteins were analyzed by SDS-PAGE and WB.

Western Blot Analysis

Tissues were weighed, homogenated, and sonicated in homogenization buffer (5 ml/g of material). Homogenates were centrifuged for 10 min at 21,000 g at 4°C. The supernatant was recovered, assayed for protein content (Bio-Rad DC Protein Assay), and kept at −80°C until use. Proteins were prepared at 2 μg/μl in 1× loading buffer with 200 mM DTT and then denatured at 99°C for 3 min. Proteins (30 μg) were separated by 10% NuPAGE precast Bis-Tris polyacrylamide minigel electrophoresis (Invitrogen) with MOPS-SDS running buffer, followed by immunoblotting analysis. Proteins were transferred to 0.45-μm nitrocellulose filters (Whatman, Buckinghamshire, UK). These were blocked with 5% low fat milk in Tris-buffered saline-Tween 20 and incubated overnight at 4°C with antibodies.

**Table 2. PCR primers used in this study**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK1ε</td>
<td>5'-tgccattttgaccatccttg-3'</td>
<td>5'-ttttaagaaaaattgcagtgagaca-3'</td>
</tr>
<tr>
<td>CK1α</td>
<td>5'-aggactgaaggctgcaacaaag-3'</td>
<td>5'-ccctttaacacacaccttcaca-3'</td>
</tr>
<tr>
<td>CK1β</td>
<td>5'-aatcctccctctgtggtgtgtcttc-3'</td>
<td>5'-taggggttggatttgcata-3'</td>
</tr>
<tr>
<td>CK1γ1</td>
<td>5'-tttccttcctctggatgttggccttc-3'</td>
<td>5'-gtctccgcttttgccttc-3'</td>
</tr>
<tr>
<td>CK1γ2</td>
<td>5'-ssncscccagagtgcagcc-3'</td>
<td>5'-ccacattgttcccttagtgcggc-3'</td>
</tr>
<tr>
<td>CK1γ3</td>
<td>5'-aaggctctgaccctctgggaa-3'</td>
<td>5'-ccacatggtttctgccgg-3'</td>
</tr>
<tr>
<td>TBP</td>
<td>5'-aggacccaaaggtgaaagacactc-3'</td>
<td>5'-ccacagttttcccttgagtt-3'</td>
</tr>
</tbody>
</table>

Affinity Chromatography Purification of CK1 on Axin Beads

Expression of GST-axin 2 fusion protein. The GST-axin 2 fusion protein (77) was expressed in *E. coli* KRX (Stratagene; Agilent Technologies, Les Ulis, France) after induction with 0.5 mM isopropryl β-D-1-thiogalactopyranoside (IPTG) at 37°C for 3 h. Bacteria were resuspended in 20–30 ml of lysis buffer, 1 mg/ml lysozyme was added, and the mix was rotated for 10 min at RT. Lysis extracts were sonicated for 2 min. Six mM MgCl2 and 25 U/ml benzonase were added and incubation ensued for 15 min at 4°C, followed by a spin at 12,000 g for 30 min at 4°C. Soluble fractions were transferred to glutathione beads, followed by a 1-h incubation at 4°C. The beads were washed with lysis buffer three times and once with BB and brought to a 20% suspension in BB. They were stored until further use at 4°C.

Purification of CK1 from kidney lysates. Kidney lysate (600 μg), prepared as described below, was incubated with 100 μl of GST-axin 2-coupled glutathione beads for 30 min at 4°C under constant rotation. The beads were washed four times with BB before the addition of 90 μl of 2× sample loading buffer (Invitrogen) with 200 mM DTT. Following heat denaturation for 3 min, the bound proteins were analyzed by SDS-PAGE and WB, as described below.

Immunoprecipitation of CK1ε and CK1α

Tissue extracts containing 400 μg of total protein were diluted in homogenization buffer to a volume of 500 μl and precleared with 25 μl of protein G sepharose beads (40% slurry in BB; Sigma-Aldrich) at 4°C for 1 h. CK1ε or CK1α were immunoprecipitated with 2 μg of CK1ε or CK1α antibodies, respectively, from precleared lysates by 1 h of incubation at 4°C, followed by 1 h of incubation at 4°C with 25 μl of protein G sepharose beads. Immunoprecipitates were washed four times with BB before the addition of 45 μl 1× sample loaded buffer with 200 mM DTT. Beads were then denatured for 3 min at 99°C. The supernatant was recovered after a 1-min centrifugation at 10,000 g. Diluted and precleared extracts were diluted to one-half in 2× sample loaded buffer containing 400 mM DTT. Immunoprecipitated proteins were analyzed by SDS-PAGE and WB.

Western Blot Analysis

Tissues were weighed, homogenized, and sonicated in homogenization buffer (5 ml/g of material). Homogenates were centrifuged for 10 min at 21,000 g at 4°C. The supernatant was recovered, assayed for protein content (Bio-Rad DC Protein Assay), and kept at −80°C until use. Proteins were prepared at 2 μg/μl in 1× loading buffer with 200 mM DTT and then denatured at 99°C for 3 min. Proteins (30 μg) were separated by 10% NuPAGE precast Bis-Tris polyacrylamide minigel electrophoresis (Invitrogen) with MOPS-SDS running buffer, followed by immunoblotting analysis. Proteins were transferred to 0.45-μm nitrocellulose filters (Whatman, Buckinghamshire, UK). These were blocked with 5% low fat milk in Tris-buffered saline-Tween 20 and incubated overnight at 4°C with antibodies.

**C Kinase assays**

<table>
<thead>
<tr>
<th>Kinase</th>
<th>IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDK1/cyclin B1</td>
<td>8.1</td>
</tr>
<tr>
<td>CDK2/cyclin E1</td>
<td>0.22</td>
</tr>
<tr>
<td>CDK5/p25</td>
<td>0.95</td>
</tr>
<tr>
<td>CDK5/p35</td>
<td>0.31</td>
</tr>
<tr>
<td>CDK7/cyclin H/MAT</td>
<td>1.20</td>
</tr>
<tr>
<td>CDK9/cyclin K</td>
<td>1.40</td>
</tr>
<tr>
<td>CDK9/cyclin T1</td>
<td>1.10</td>
</tr>
<tr>
<td>CDK12/cyclin K</td>
<td>1.20</td>
</tr>
<tr>
<td>CDK17/p35</td>
<td>22.00</td>
</tr>
<tr>
<td>CDK19/cyclin C</td>
<td>&gt;100</td>
</tr>
<tr>
<td>CDK20/cyclin T1</td>
<td>13.00</td>
</tr>
<tr>
<td>CK1α</td>
<td>20.00</td>
</tr>
<tr>
<td>CK1γ1</td>
<td>19.00</td>
</tr>
<tr>
<td>CK1γ2</td>
<td>5.70</td>
</tr>
<tr>
<td>CK1γ3</td>
<td>12.00</td>
</tr>
<tr>
<td>CK1δ</td>
<td>1.30</td>
</tr>
<tr>
<td>CK1ε</td>
<td>3.30</td>
</tr>
</tbody>
</table>
ate secondary antibodies conjugated to horseradish peroxidase (Bio-Rad) were added to visualize the proteins using the enhanced chemiluminescence reaction.

**Protein Kinase Assays**

CK1ε or CK1α was immunoprecipitated as described above. After three washes, beads and immobilized immunoprecipitates were washed two times with buffer C. The catalytic activity of CK1 bound to beads was assayed in buffer C with 50 μM CK-S peptide (RRKHAAILGPSAYSTIA; phosphorylated serine (pS); Proteogenix, Schiltigheim, Germany) in the presence of 15 μM cold ATP (Sigma-Aldrich) + [γ-32P] ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume of 30 μl. The reaction was started by addition of the substrate and ATP mix. Tubes were incubated at 30°C for 30 min. During incubation, tubes were shortly vortexed every 2 min. At the end of the incubation, tubes were briefly centrifuged at 9,600 g, and the reaction was stopped by spotting 25 μl of the reaction mix onto P81 phosphocellulose Whatman filters (Merck Millipore, Darmstadt, Germany), which were washed five times in 1% phosphoric acid. Their radioactivity was measured by a scintillation counter Tri-Carb 2800TR (Perkin-Elmer, Waltham, MA) in the presence of 1 ml of scintillation fluid (Ultima Gold XR; Perkin-Elmer). Kinase activities were expressed in counts per minute incorporated for 30 min.

**Kinase Selectivity Panel**

The IC50 profile of roscovitine and CR8 was determined in a biochemical activity assay using 17 protein kinases by ProQinase (D-79106; Freiburg, Germany). IC50 values were measured by testing 10 semi-log concentrations of the compounds in singlicate in each kinase assay ranging from 3 nM to 100 μM. The final DMSO concentration in the reaction cocktails was 1% in all cases.

A radiometric protein kinase assay (33PProQinase Activity Assay) was used for measuring the kinase activity of the 17 protein kinases. All kinase assays were performed in 96-well FlashPlates from Perkin-Elmer (Boston, MA) in a 50-μl reaction volume. The assay for all protein kinases contained 70 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, ATP (variable amounts, corresponding to the apparent ATP-Km of the respective kinase), γ-32P-ATP, protein kinase, and substrate.

All protein kinases provided by ProQinase were expressed in Sf9 insect cells or in E. coli as recombinant GST fusion proteins or His-tagged proteins either as full-length or enzymatically active frag-

---

**Fig. 2.** Affinity chromatography purification of roscovitine and CR8 targets from various mouse tissues. Extracts of healthy tissues (brain, kidney, liver, lung, stomach, intestine, colon, heart, muscle, spleen, thymus, ovary, testis, and skin) were prepared and loaded on immobilized roscovitine (R) and CR8 (C). Beads were extensively washed and the bound proteins resolved by SDS-PAGE (4 different 12-well gels), followed by silver staining (A) and Western blotting (WB; B), using antibodies directed against glucose-debranching enzyme (GDE), casein kinase 1ε (CK1ε), cyclin-dependent kinase (CDK)5 and CDK9, extracellular-regulated kinase 2 (ERK2), and pyridoxal kinase (PDXK). Note the high CK1ε expression in brain compared with kidney (the latter is not visible due to the short exposure required to avoid oversaturation of the brain CK1ε signal). Vertical dotted lines separate the 4 different gels and 4 different WB assembled in A and B.
mements. All kinases were produced from human cDNAs. Kinases were purified by either GSH-affinity chromatography or immobilized metal affinity chromatography. Affinity tags were removed from a number of kinases during purification. The purity of the protein kinases was examined by SDS-PAGE/Coomassie staining, and the identity was checked by mass spectroscopy. CK1 isofoms were obtained from Life Technologies (Invitrogen).

The reaction cocktails were incubated at 30°C for 60 min. The reaction was stopped with 50 μl of 2% (vol/vol) H2PO4, and plates were aspirated and washed two times with 200 μl 0.9% (wt/vol) NaCl. Kinase activity-dependent transfer of β3P (counting of "counts/min") was determined with a microplate scintillation counter (Microbeta; Wallac). All assays were performed with a Beckman Coulter Biomek 2000/SL robotic system.

RNA Isolation and Real-Time RT-PCR

Total RNA was isolated from tissue using the RNeasy Plus kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Total RNA (1 μg) was reverse transcribed by the SuperScript VILO cDNA synthesis kit (Invitrogen, Cergy Pontoise, France) in accordance with the manufacturer’s instructions. RNA expression profiles were analyzed by real-time quantitative PCR using SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA) in a CFX96 Touch real-time PCR detection system (Bio-Rad). Primers used for the detection of Ck1ε, Ck1α, Ck1β, Ck1γ1, Ck1γ2, and Ck1γ3 genes and housekeeping gene Tbp are listed in Table 2 (Eurofins, Ebersberg, Germany). The complete reactions were subjected to the following program of thermal cycling: 1 cycle of 30 s at 95°C and 50 cycles of 5 s at 95°C and 5 s at 60°C. A melting curve was run after the PCR cycles, followed by a cooling step. Each sample was run in duplicate in each experiment. Expression levels of Ck1ε, Ck1α, Ck1β, Ck1γ1, Ck1γ2, and Ck1γ3 were normalized to the expression level of Tbp.

Histopathology and Image Analysis

Kidneys, cut through the middle, were fixed in 4% buffered formaldehyde and dehydrated and embedded in paraffin wax at 56°C with Exclor (Thermofisher). Paraaffin-embedded samples were cut into sections of 5-μm thickness and stained by hematoxylin and eosin. Three sections separated by 50 μm were analyzed for each kidney. The histological slides were converted to digital slides with a digital slide scanner (Hamamatsu NDP) and analyzed with NIS-Elements software (Nikon). After calibration, kidney and cyst segmentation was performed by thresholding, and the same threshold was performed for all slices. Regions of interest were defined by manual delineation of borders. Total cyst area and cyst number were quantified to calculate the mean cyst area per kidney section.

Statistical Analysis

Statistical analysis was evaluated using Student’s t-test (computed using GraphPad Prism 5 software). A P value = 0.01 to 0.05 was considered significant, a P value = 0.001 to 0.01 was considered very significant, and a P value of <0.001 was considered extremely significant.

RESULTS

CK1s as Targets of Roscovitine and CR8 in Kidneys

The DiscoveRx KinomeScan interaction assay (17), which includes 402 kinases, revealed the interaction of roscovitine and CR8 (Fig. 1A) with CK1 isofoms (23). Kd determinations showed specificity for CK1α, CK1β, and CK1ε (Fig. 1B). The effects of roscovitine on a range of CDKs and CK1s were evaluated in vitro and IC50 values determined from dose-
response curves (Fig. 1C), showing a preference of roscovitine for CDK2, CDK5, CDK7, CDK9, CK1ε, and CK1α.

Affinity Purification of Kidney Drug Targets on Immobilized Roscovitine and CR8

To identify the targets of roscovitine and CR8 in healthy and polycystic kidneys, we used an affinity chromatography method exploited previously with various CDK inhibitors (3, 47). Compounds were immobilized through a linker on agarose beads. Extracts of healthy mouse tissues were loaded on immobilized roscovitine or CR8, the beads were washed extensively, and the bound proteins were resolved by SDS-PAGE, followed by silver staining and Western blotting (Fig. 2). Results show a panel of targets that vary strikingly in terms of identity and/or quantity according to tissue type (Fig. 2).

We next investigated roscovitine and CR8 targets in kidneys using healthy and polycystic renal tissue. The latter derived from ADPKD patients and from jck (C57BL/6J) mutant mice (9 wk old). Kidney extracts were prepared and analyzed by SDS-PAGE/silver staining. Despite gross morphological differences between healthy and polycystic kidneys, the global protein pattern remained quite similar in the absence or presence of cysts (data not shown).

Kidney extracts were next loaded onto immobilized roscovitine or CR8, beads were washed extensively, and bound proteins were resolved by SDS-PAGE, followed by silver staining (data not shown) and WB using antibodies against CDK2, -5, -7, and -9, glucose-debranching enzyme (GDE), CK1ε, CK1α, ERK1/2, and pyridoxal kinase (PDXK) (data not shown). Extracts were also loaded onto axin-1 and axin-2 agarose beads, which bind glycogen synthase kinase 3 (GSK-3) (data not shown). Results show a panel of targets that vary strikingly in terms of identity and/or quantity according to tissue type (Fig. 2).
The CK1ε isoform pattern is modified similarly in all PKD models. Extracts were prepared from kidneys of mouse PKD and corresponding WT animals and analyzed directly (crude extract) or following affinity purification on CR8-agarose beads. SDS-PAGE was followed by WB with antibodies directed against CK1ε. The nonpolycystic nephronophthisis model, used as a control, displayed no change in CK1ε expression or isoforms pattern. Thin lines in the blots indicate the position of the 39-kDa MWM. Crude extracts and CR8-purified proteins, separated by a MWM lane, were run on the same gel, and a single WB blot was carried out for all 4 samples for each mouse model. In Thm1-cKO samples, because of important signal intensity differences, different exposures were necessary for crude extracts and CR8-purified proteins. The 2 WBs, assembled in a single panel, are thus separated by a vertical dotted line. In Pkd2-cKO samples, crude extracts and CR8-agarose were not separated by MWM, and the WB was cut and separated by a blank space delineated by a vertical dotted line.

Increased in polycystic extracts. No differences in GDE, ERK1/2, PDXK, or GSK-3 were seen (data not shown).

CK1ε Is Overexpressed While the CK1α Isoforms Pattern Is Altered in Polycystic Kidneys

In contrast, the level of CK1ε was consistently increased in both human and mouse polycystic kidneys, whereas the electrophoretic pattern of CK1ε was consistently modified (decrease of the lower band, increase of middle and upper bands), as seen after affinity purification on roscovitine-agarose, CR8-agarose, and axin-2-agarose (Fig. 3, A–C). Binding specificity was demonstrated in competition experiments with various inhibitors (Fig. 4). CK1ε was next immunoprecipitated (with/without protein A-agarose preclearing) from healthy and jck polycystic kidneys by a specific antibody. WB analysis revealed strong CK1ε induction (Fig. 3D). The same experiment was performed with anti-CK1α antibodies. Preclearing maintained the change in CK1α pattern seen in polycystic vs. healthy kidneys (data not shown). Only the upper form of CK1α was immunoprecipitated (data not shown).

To determine whether aberrant expression pattern of CK1ε and CK1α is a general characteristic of cystic kidneys regardless of the genetic mutation, we investigated the expression of CK1ε and CK1α in a variety of PKD mouse models (Figs. 5 and 6). Extracts of cystic and unaffected kidneys from the corresponding mouse strain were prepared and analyzed by
WB as crude extracts or following purification on CR8-agarose. CK1ε was overexpressed (Fig. 5), whereas the CK1α isoforms pattern was modified (Fig. 6) in a similar fashion in all PKD models. In contrast, no changes in CK1ε expression or in CK1α isoform patterns were observed in the Nphp4-knockout (KO) mouse model of nephronophthisis, which does not develop cysts. In parallel, p21cip1 (a natural CDK2 inhibitor), CDK2, CDK5, and CDK9 expression was analyzed in the same crude extracts and/or following CR8-agarose affinity purification. Expression of p21cip1 was always reduced in polycystic kidneys. CDK2 expression was very stable almost always increased (data not shown).

In contrast, p21cip1 expression was increased in the Nphp4-KO kidney extracts. CDK2 expression was very stable in all PKD models (Fig. 7), whereas that of CDK5 was increased in seven of 11 tested PKD models and that of CDK9 isoforms remains constant.

The mRNA levels of all CK1 isoforms in the kidneys of jck and Pkd1-conditional knockout (cKO) mice, and their wild-type (WT) littermates, were quantified by Q-PCR, using TBP (TATA-binding protein) as a house-keeping reference mRNA (Ref. 67 and Billot K, Coquil C, and Meijer L, unpublished data). In contrast, p21cip1 expression was increased in the NPHP4-KO kidney extracts. CDK2 expression was very stable in all PKD models (Fig. 7), whereas that of CDK5 was increased in seven of 11 tested PKD models and that of CDK9 almost always increased (data not shown).

**Fig. 8.** CK1ε mRNA expression is increased in representative PKD models. A: mRNA expression levels of all CK1 isoforms in kidneys of jck and wild-type (WT) mice were quantified by PCR. The values were normalized on the basis of TATA-binding protein (TBP) mRNA levels and presented as fold change of polycystic over WT kidney levels. B: expression levels of all CK1 isoforms in Pkd1-cKO and control mouse kidneys. C: expression levels of CK1ε and CK1δ isoforms in the kidneys of various PKD models, normalized with TBP mRNA levels and presented as fold change of polycystic over healthy kidneys levels. Horizontal dotted line indicates identical level of expression for healthy and polycystic kidneys. Number of different kidneys (WT/PKD): 2/3 (Jck), 3/3 (Bpk), 2/2 (KspCre), 4/4 (Tag26), 2/2 (Extra 11), 4/4 (Pkd1cKO), 3/3 (Pcy3), 2/2 (Pkd2cKO), 4/4 (Cpk), 4/4 (Hnf1β), 5/4 (Thm1cKO), and 3/3 (Nphp4). Tested in triplicate. *P = 0.01–0.05, **P = 0.001–0.01, and ***P < 0.001 (Student’s t-test).
**Tissue Distribution of CK1ε and CK1α Expression Changes**

We analyzed CK1ε and CK1α mRNA levels in various jck and Pkd1-cKO mouse tissues, relative to levels of wild-type (WT) littermates (Fig. 9, A and B). CK1ε mRNA was overexpressed in polycystic kidneys but not in other tissues. In healthy mice the CK1ε protein is expressed mostly in brain, lung, and heart (Fig. 2). We analyzed protein levels of CK1ε, CK1α, and p21cip1 in kidneys, liver, heart, and brain of jck and Pkd1-cKO mice and healthy WT animals (Fig. 9, C and D). An increase in CK1ε expression, a change in CK1ε isoform pattern and a decrease in p21cip1 expression were seen in the kidneys of both polycystic models compared with WT littermates, but these changes were not present in liver, heart, or brain (Fig. 9C). In polycystic animals, CK1ε and CK1α expression changes are thus limited to the kidneys. It is surprising that no changes were seen in the liver (Fig. 9C), since polycystic liver is frequently observed associated with PKD. Nevertheless, this lack of expression changes correlates well with the very modest increases in liver CK1ε and CK1α catalytic activities (Fig. 10, C and D). Differences in timing of expression/activity changes between kidney and liver may explain these differences.

**Time Course of CK1ε and CK1α Expression Changes**

A time course of CK1 expression changes during disease progression was charted in jck mouse kidneys collected from 26 to 64 days after birth (Fig. 10). Histological analysis and quantification of cyst surface area illustrate the development of cysts over time (Fig. 10, A and B). CK1ε mRNA levels were already upregulated at the very first time point and continuously increased in parallel with increased cystic volume (Fig. 10C). In contrast CK1α mRNA levels remained constant throughout the time course (Fig. 10D). WB analysis of CR8-agarose purified proteins showed that CK1ε protein expression is already increased 26 days after birth (first time point), whereas the CK1α isoform pattern appears to shift progressively with time (Fig. 10E).

**CK1ε and CK1α Catalytic Activities Are Increased in Polycystic Kidney Disease**

We next analyzed the catalytic activity of CK1ε and CK1α in polycystic and healthy kidneys (Fig. 11). CK1ε and CK1α were immunopurified with specific antibodies from kidneys of jck, Pkd1-cKO, Thm1-cKO, and Nphp4-KO mice and their WT littermates. Kinase activities were assayed using 33P-ATP and CK-S peptide as substrates. Results show increased catalytic activities for both CK1ε (Fig. 11A) and CK1α (Fig. 11B) in the kidneys of the three PKD models, but not of the nephronophthisis model. Note that the basal activity of CK1ε was 25- to 50-fold lower than that of CK1α. Next, kinase activity assays were run following CK1ε and CK1α immunopurification from different tissues of polycystic Pkd1-cKO mice (Fig. 11, C and D). Results...
show that only kidneys displayed enhanced CK1ε and CK1α activity (Fig. 11, C and D), confirming the renal specificity of CK1ε and CK1α altered expression. Because the antibodies directed against CK1α only immunoprecipitated the upper form (data not shown), we can say only that the catalytic activity of this CK1α isoform is increased in polycystic kidneys. We have no access to the catalytic activity of the two lower forms of CK1α.
DISCUSSION

**CK1 Kinases in Cystogenesis and PKD**

This article reports a systematic increase in the catalytic activities of CK1ε and CK1α in polycystic kidneys compared with healthy kidneys. Enhanced kinase activity correlates with increased protein and mRNA expression for CK1ε and a shift in the isoform pattern for CK1α. These modifications of CK1ε and CK1α expressions were observed in 11 PKD mouse models but not in a NPHP4-cKO nephronophthisis model. Enhanced CK1ε protein and mRNA expression levels were also detected in human ADPKD kidneys compared with healthy kidneys (data not shown). We also confirm the inhibition of CK1s by roscovitine and CR8, two kinase inhibitors initially developed against CDKs (5, 6, 19, 58–60), which reduced cystogenesis and preserved renal functions in various animal models of PKD (13, 14, 66, 67, 85). Renal CK1ε and CK1α thus represent additional targets of roscovitine and CR8.

The CK1 family comprises seven members of ubiquitously expressed, highly conserved kinases playing a large diversity of cellular functions (reviewed in Refs. 21 and 46) CK1s have been reported to be involved in Wnt (reviewed in Refs. 21, 22, 24, 41, 46, 75, and 91), Hedgehog (Hh) (reviewed in Refs. 41, 42, and 81), and mTor signaling (reviewed in Refs. 29, 40, 44, 51, and 99), all of which are involved in cystogenesis.

The polycystin complex mediates Wnt signaling (45), a pathway involving both GSK-3 and CK1 (reviewed in Refs. 22 and 41), and axin, a scaffolding protein binding both kinases (75). GSK-3 phosphorylates polycystin 2 at Ser76, thereby controlling its membrane localization (83). GSK-3 activity has been demonstrated to contribute to cystogenesis (84), and GSK-3 is regulated by a cAMP- and CREB-mediated process (43). CK1 acts as a “priming kinase” for some substrates that then become accessible to phosphorylation by GSK-3 (15). CK1 thus indirectly controls GSK-3 substrates availability.

CK1 phosphorylates several proteins involved in Hh signaling (reviewed in Ref. 41), namely the smoothened (Smo) signal transducer (16, 28, 42) and the fused (Fu) (98) and Gli proteins (Ci/Gli) (71, 81). Through these phosphorylations, CK1 primes Smo activity, activates Fu, and regulates Ci/Gli processing (reviewed in Refs. 22). CK1 thus indirectly controls GSK-3 substrates availability.

This article reports a systematic increase in the catalytic activities of CK1ε and CK1α in polycystic kidneys compared with healthy kidneys. Enhanced kinase activity correlates with increased protein and mRNA expression for CK1ε and a shift in the isoform pattern for CK1α. These modifications of CK1ε and CK1α expressions were observed in 11 PKD mouse models but not in a NPHP4-cKO nephronophthisis model. Enhanced CK1ε protein and mRNA expression levels were also detected in human ADPKD kidneys compared with healthy kidneys (data not shown). We also confirm the inhibition of CK1s by roscovitine and CR8, two kinase inhibitors initially developed against CDKs (5, 6, 19, 58–60), which reduced cystogenesis and preserved renal functions in various animal models of PKD (13, 14, 66, 67, 85). Renal CK1ε and CK1α thus represent additional targets of roscovitine and CR8.

The CK1 family comprises seven members of ubiquitously expressed, highly conserved kinases playing a large diversity of cellular functions (reviewed in Refs. 21 and 46) CK1s have been reported to be involved in Wnt (reviewed in Refs. 21, 22, 24, 41, 46, 75, and 91), Hedgehog (Hh) (reviewed in Refs. 41, 42, and 81), and mTor signaling (reviewed in Refs. 29, 40, 44, 51, and 99), all of which are involved in cystogenesis.
Mammalian target of rapamycin (mTOR) is clearly involved in cystogenesis, and despite some controversy, inhibiting mTOR remains a promising therapeutic approach (reviewed in Refs. 29, 40, 44). CK1α is part of an autoamplification loop for mTOR signaling (26). Following a priming phosphorylation by mTOR, the mTOR inhibitor DEPTOR is phosphorylated by CK1α, leading to its proteosomal degradation. Thus mTOR triggers the CK1α-dependent destruction of its inhibitor, leading to enhanced mTOR kinase activity. Downregulation of CK1 activity is thus expected to reduce mTOR signaling.

CK1 is also involved in cell proliferation (reviewed in Ref. 46). For example, CK1ε promotes cell proliferation through 4E-BP1 phosphorylation-dependent regulation of translation (82) and through its action on Wnt signaling (96). Another example is provided by Jade-1S, a protein highly expressed in kidney epithelial cells, which is especially concentrated in primary cilia and centrosomes (12). Jade-1S has several functions associated with injury repair: regulation of Wnt signaling, DNA transcription and epigenetic modifications. CK1ε phosphorylation of Jade-1S at Ser377 turns off its chromatin remodeling functions, allowing cell cycle progression. Prevention of CK1ε-mediated Jade-1S phosphorylation alters the interactome profile of Jade-1S (the mitotic kinase PLK1 and Jade-1S interact in a CK1ε-dependent manner) and is accompanied by impaired cell proliferation (12).

The primary cilium is central to cystogenesis (reviewed in Refs. 2, 10, 36, 39, 54, 55, and 68), and CK1ε was identified in a global proteome study of the primary cilium (61). CK1ε was identified in a proteomic study of human airway ciliary axonemes (8). CK1ε (50), CK1α (16), and CK1δ (34) play a role in cilia stability, although many molecular details still need clarification. Taken together, the literature and our results support essential roles of CK1 isoforms in key pathways involved in cilia function and cystogenesis.

**CDK/CK1 Dual-Specificity Inhibitors**

Various CDKs play a role in cystogenesis in both controlling cell proliferation and regulating cilia functions. The mTOR inhibitor rapamycin downregulates the expression of CDK1 and several cyclins, reduces cyst growth and improves kidney function in a Pkd2-cKO model (51). CDK2 expression and activity levels have not been investigated in PKD. However, several reports show that p21^{cyc} expression is decreased in polycystic kidneys (7, 53, 67). We confirmed reduced p21^{cyc} expression in 11 PKD mouse models (Fig. 7) as well as in

---

**Fig. 12. Roscovitine and CR8 reduce cystogenesis through combined inhibition of CDKs and CK1s, a working hypothesis for the development of a kinase inhibitor drug candidate.**

A: in polycystic kidneys, 1) CDK5 levels have been reported to be increased, and CDK5 is involved in cell proliferation and cystogenesis; 2) p21^{cyc} expression is reduced, leading to enhanced CDK2 activity, and furthermore, CDK2 phosphorylates p21^{cyc} on Ser78, leading to its inactivation; 3) CDK9 expression is enhanced and may contribute to MYC overexpression in conjunction with CDK7 (both kinases contribute to maintain Mcl-1 expression; decreased p21^{cyc}, increased CDK2, and increased MYC all contribute to enhanced proliferation, and elevated Mcl-1 acts to prevent apoptotic cell death; 4) CK1ε protein level is increased whereas the CK1α isoform pattern is modified, resulting in enhanced kinase activity of both CK1s. CK1s have been reported to be involved in cell proliferation and in mammalian target of rapamycin (mTOR), Hedgehog, and Wnt signaling, all shown to be implicated in cystogenesis. Furthermore, CK1 acts as a “priming kinase” by phosphorylating substrates that then become available for phosphorylation by GSK-3, a kinase also reported to play a key role in cystogenesis. B: Reduction of CDK5, CDK2, CDK7, and CDK9 catalytic activities by roscovitine and CR8 is expected to lead to reduced cell proliferation, induction of apoptosis, and reduced cystogenesis. Reduction of CK1ε and CK1α catalytic activities by roscovitine and CR8 is expected to lead to reduced cell proliferation, altered mTOR, Hedgehog, and Wnt signaling, reduced substrate phosphorylation by GSK-3, and ultimately reduced cystogenesis.
kids from human patients with ADPKD (data not shown). We can expect CDK2 activity to be increased, despite stable expression, as a consequence of reduced p21cip1 expression. Furthermore, in a feedback loop, CDK2 inactivates p21cip1 by phosphorylating its Ser37 residue (38). Tumor necrosis factor-α (TNFα), present in cyst fluid, downregulates p21cip1 expression and consequently promotes cyst-lining epithelial cell proliferation (97). A PKD2 mutant cell line showed reduced expression of p57kip2, another natural CDK2 inhibitor, and increased CDK2 levels (30). Interestingly, the cilary kinase NEK8 participates in the maintenance of genomic stability by reducing CDK2/cyclin A activity. Loss of NEK8 activity (as seen in some ciliopathies, including PKD and nephronophthisis) results in increased CDK activity and DNA damage (18, 33). By inhibiting CDK2 activity directly, CDK inhibitors are expected to compensate for the reduction in p21cip1 levels and, therefore, to prevent cell proliferation. CDK5 expression was reported to be increased in jck kidneys (14). We saw upregulation in seven models out of 11 tested (data not shown). Is this differential expression linked to the severity of the disease? CDK5 phosphorylates the centrosomal phosphoprotein NDE1, a negative regulator of cilia length, at Thr191, targeting NDE1 for ubiquitinylation by the E3 ubiquitin ligase FBW7 and destruction (56). CDK5 or FBW7 depletion stabilizes NDE1 and reduces cilia length (56). Crossing jck mice with CDK5-cKO mice unambiguously demonstrates that CDK5 activity regulates ciliary length and contributes to cysts formation (30). Inhibition of CDK5 by roscovitine/CR8 may thus contribute to reduce cystogenesis. CDK9 expression was increased in the kidneys of most of the polycystic models we investigated (data not shown). Along with CDK7, CDK9 controls RNA polymerase and thus short-lived proteins. We reported in another context that CDK9/CDK7 inhibition by roscovitine and CR8 leads to reduced expression of Myc (23) and McI-1 (5), which contribute to cell proliferation and apoptosis, respectively. Mcy overexpression in PKD has been described in detail (reviewed in Ref. 88; also see Refs. 20, 31, and 88–92). Inhibition of CK1ε by chemical inhibitors or shRNA prevented the phosphorylation of 4E-BP1 and reduced c-Myc expression in cell lines (25). We do not know whether roscovitine treatment will lead to a reduction of Mcy and McI-1 in vivo, which would contribute to reduce cell proliferation and enhance apoptosis. Inhibiting CDKs is further encouraged by recent identification of multiple CDK inhibitors in an in vitro three-dimensional cystogenesis screen (11).

In summary, our results suggest that roscovitine and CR8 may exert their beneficial effects on polycystic kidneys through a dual action (Fig. 12): 1) inhibition of several CDKs, leading to reduced proliferation and enhanced apoptosis; and 2) inhibition of CK1ε and CK1α, leading to inhibition of proliferation, altered Wnt, Hh, and mTOR signaling, and indirect inhibition of GSK-3. Development of pharmacological inhibitors with an optimal balance of kinase inhibition between the different CDK and CK1 isoforms is likely to be relevant for controlling PKD progression.

ACKNOWLEDGMENTS

We thank Marco Chiariavalli and Flora Legendre for technical help, Dr. Dorien Peters for the CRE mice used to delete HNFIβ, Dr. Tomoichiro Asano for the anti-GDE antibody, and Corinne Lagrangeuil for continuous support. We are grateful to Laurent Doucet (Service Anatomo-Pathologie) and Emmanuel Chafara (Service de Néphrologie, Centre Hospitalier de Brest) for providing human ADPKD kidneys.

GRANTS

This work was made possible through the support of grants from the Polycystic Kidney Foundation, “La Fondation PKD France,” and PKD-STOP (FEDER-Conseil Régional de Bretagne) to L. Meijer and from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; R01-DK-103033) to P. Tran.

This work was also supported by NIDDK Grants R01-DK-078043 and R01-DK-109563) and a gift from the Lillian Goldman Charitable Trust to T. Weinman.

DISCLOSURES

L. Meijer and N. Oumata are coinventors on the CR8 patent. L. Meijer is an inventor on the roscovitine patent. L. Meijer is co-founder, Chair and CSO, of ManRos Therapeutics. The other authors have no conflicts of interest to disclose.

AUTHOR CONTRIBUTIONS


REFERENCES


AJP-Renal Physiol doi:10.1152/ajprenal.00489.2017 • www.ajprenal.org
Downloaded from www.physiology.org/journal/ajprenal by ${individualUser.givenNames} ${individualUser.surname} (193.054.110.055) on July 10, 2018. Copyright © 2018 American Physiological Society. All rights reserved.


AJP-Renal Physiol • doi:10.1152/ajprenal.00489.2017 • www.ajprenal.org
CK1 IN POLYCYSTIC KIDNEY DISEASE

Masyuk TV, Masyuk AI, LaRusso NF.

Kühn WE, Walz G.

Park JY, Park SH, Weiss RH.


Ma M, Tian X, Igarashi P, Pazour GJ, Somlo S.

Oumata N, Ferandin Y, Meijer L, Galons H.

Santoro D, Pellicanò V, Visconti L, Trifirò G, Buemi M, Cernaro V.


Copyright © 2018 American Physiological Society. All rights reserved.

F72


Copyright © 2018 American Physiological Society. All rights reserved.

Copyright © 2018 American Physiological Society. All rights reserved.

AJP-Renal Physiol • doi:10.1152/ajprenal.00489.2017 • www.ajprenal.org

Downloaded from www.physiology.org/journal/ajprenal by [individualUser.givenNames] [individualUser.surname] (193.054.110.055) on July 10, 2018.

Copyright © 2018 American Physiological Society. All rights reserved.


